Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

Abstract
The optimal strategy for thromboprophylaxis after major joint replacement has not been established. Low-molecular-weight heparins such as enoxaparin predominantly target factor Xa but to some extent also inhibit thrombin. Apixaban, a specific factor Xa inhibitor, may provide effective thromboprophylaxis with a low risk of bleeding and improved ease of use.

This publication has 19 references indexed in Scilit: